Syntis Bio has raised $33 million in Series A financing, led by Cerberus Ventures, with additional investment from Mansueto Investments, Woori Venture Partners, Apollo Labs, and existing investors. The company also received up to $5 million in grant funding from the NIH Small Business Innovation Research programme. The funding will support the advancement of Syntis Bio’s SYNT technology platform, including the development of SYNT-101 for obesity and SYNT-202 for homocystinuria.

The SYNT platform is designed to deliver oral therapies that can act in the gastrointestinal tract for up to 24 hours. Preclinical and early human studies for SYNT-101 showed effects on satiety hormones, weight loss, and muscle mass retention. The company plans to advance SYNT-101 into Phase 1 trials and begin preclinical studies for SYNT-202.